MAPK14
MOLECULAR TARGETmitogen-activated protein kinase 14
MAPK14 (mitogen-activated protein kinase 14) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MAPK14
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Sorafenib | 2.89 | 17 |
| 2 | Dasatinib | 1.39 | 3 |
| 3 | Afatinib | 1.10 | 2 |
| 4 | egcg | 0.69 | 1 |
| 5 | fisetin | 0.69 | 1 |
| 6 | myricetin-3-O-galactopyranoside [Supplementary Concept] | 0.69 | 1 |
| 7 | Quercetin | 0.69 | 1 |
| 8 | Anisomycin | 0.69 | 1 |
| 9 | Celecoxib | 0.69 | 1 |
| 10 | isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside [Supplementary Concept] from | 0.69 | 1 |
| 11 | tyrphostin ag 1478 | 0.69 | 1 |
| 12 | withaferin | 0.69 | 1 |
About MAPK14 as a Drug Target
MAPK14 (mitogen-activated protein kinase 14) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented MAPK14 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MAPK14 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.